(Q37879701)

English

Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection.

scientific article published on 25 May 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

Europe PubMed Central

Translating pharmacogenetics into clinical practice: interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

0 references

Hepatitis C virus

1 reference

based on heuristic

inferred from title

Elisabetta Cariani

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

Cristina Rota

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Rosina Critelli

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Tommaso Trenti

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

publication date

25 May 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Clinical Chemistry and Laboratory Medicine

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

49

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1247-1256

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21612542%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Global burden of disease (GBD) for hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The epidemiology of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Seroprevalence, viremia and genotype distribution of hepatitis C virus: a community-based population study in northern Italy

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The importance of HCV on the burden of chronic liver disease in Italy: a multicenter prevalence study of 9,997 cases.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Chronic hepatitis C virus infection: genotyping and its clinical role

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatitis C virus genotypes in France: relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon-based therapy for chronic hepatitis C: current and future perspectives

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Impact of obesity on treatment of chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Replicated association between an IL28B gene variant and a sustained response to pegylated interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Immunological determinants of the outcomes from primary hepatitis C infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B and the control of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B SNP rs8099917 is strongly associated with pegylated interferon-α and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A whole-genome association study of major determinants for host control of HIV-1

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A haplotype map of the human genome

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B genomic-based treatment paradigms for patients with chronic hepatitis C infection: the future of personalized HCV therapies

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL-28A, IL-28B, and IL-29: promising cytokines with type I interferon-like properties

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon signaling and treatment outcome in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The recent breakthroughs in the understanding of host genomics in hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interleukin-28b: a key piece of the hepatitis C virus recovery puzzle

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

What have we learned from the IL28 receptor knockout mouse?

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hepatitis C pharmacogenetics: state of the art in 2010.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Ribavirin treatment for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

A pilot study of ribavirin therapy for chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon- alpha

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Factors contributing to ribavirin-induced anemia

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Factors influencing ribavirin-induced hemolysis

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Functional study of the P32T ITPA variant associated with drug sensitivity in humans.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Pharmacogenetic significance of inosine triphosphatase

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Individual variation in inosine triphosphate accumulation in human erythrocytes

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/3 but do not decrease dose reductions of RBV or increase SVR.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

ITPA gene variant protects against anemia induced by pegylated interferon-α and ribavirin therapy for Japanese patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.618

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37879701&oldid=1605217066"